---
figid: PMC6247470__OMCL2018-1098617.003
figtitle: Paeonol protects against atherogenesis
organisms:
- Candida dubliniensis
- Panax notoginseng
- Paeonia suffruticosa
- Bupleurum falcatum
- Angelica dahurica
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Oryctolagus cuniculus
- Coturnix coturnix
pmcid: PMC6247470
filename: OMCL2018-1098617.003.jpg
figlink: /pmc/articles/PMC6247470/figure/fig3/
number: F3
caption: 'Schematic diagram of molecular mechanism underlying paeonol protects against
  atherogenesis. Paeonol-induced ROS elimination is associated with inhibition of
  NOX/ROS pathway. Paeonol mainly suppresses the MAPKs and NF-κB cascade to weaken
  inflammatory responses and EC apoptosis. In addition, paeonol activates PPAR-α/CPT-1
  pathway and represses SREBP-1c signaling to accelerate TG catabolism and block TG
  synthesis, respectively. Then, paeonol weakens foam cell formation by increasing
  level of reverse transport axis LXRα/ABCA1 and reducing activities of JNK signaling
  involved in CD36 production. Moreover, paeonol mediates autophagic factors and cell
  cycle-related single molecules to block the VSMC proliferation via the AMPK/mTOR
  pathway. TLR4: Toll-like receptor 4; MyD88: myeloid differentiation primary response
  protein 88; AMPKα: AMP-activated protein kinase α; HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme
  A reductase; BMP4: bone morphogenic protein 4; PPARδ: peroxisome proliferator-activated
  receptor δ; eNOS: endothelial nitric oxide synthase; NOX: NADPH oxidase; Sirt1:
  sirtuin 1; LOX-1: lectin-like low-density lipoprotein receptor-1; JNK: c-jun N-terminal
  kinase; NF-κB: nuclear factor kappa B; PI3K: phosphatidylinositol 3-kinbase; MAPKs:
  mitogen-activated protein kinases; LPS: lipopolysaccharides; CPT-1: carnitine palmitoyltransferase
  I; FAS: fatty acid synthetase; ACCα: acetyl CoA carboxylase α; SREBP-1c: sterol
  regulatory element-binding protein 1c; MKK: mitogen-activated protein kinase kinase;
  ABCA1: ATP-binding cassette transporter A1; LXRα: liver X receptor α; PDGF: platelet-derived
  growth factor; ERK1/2: extracellular signal-regulated kinase 1/2; mTOR: mammalian
  target of rapamycin; LC3II: microtubule-associated protein 1 light chain 3 II; LDLR:
  low-density lipoprotein receptor; CYP7A1: cholesterol 7 alpha-hydroxylase.'
papertitle: Beneficial Effects Exerted by Paeonol in the Management of Atherosclerosis.
reftext: Li Lu, et al. Oxid Med Cell Longev. 2018;2018:1098617.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9219933
figid_alias: PMC6247470__F3
figtype: Figure
organisms_ner:
- Rattus norvegicus
- Oryctolagus cuniculus
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC6247470__F3
ndex: 554f072a-df0e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6247470__OMCL2018-1098617.003.html
  '@type': Dataset
  description: 'Schematic diagram of molecular mechanism underlying paeonol protects
    against atherogenesis. Paeonol-induced ROS elimination is associated with inhibition
    of NOX/ROS pathway. Paeonol mainly suppresses the MAPKs and NF-κB cascade to weaken
    inflammatory responses and EC apoptosis. In addition, paeonol activates PPAR-α/CPT-1
    pathway and represses SREBP-1c signaling to accelerate TG catabolism and block
    TG synthesis, respectively. Then, paeonol weakens foam cell formation by increasing
    level of reverse transport axis LXRα/ABCA1 and reducing activities of JNK signaling
    involved in CD36 production. Moreover, paeonol mediates autophagic factors and
    cell cycle-related single molecules to block the VSMC proliferation via the AMPK/mTOR
    pathway. TLR4: Toll-like receptor 4; MyD88: myeloid differentiation primary response
    protein 88; AMPKα: AMP-activated protein kinase α; HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme
    A reductase; BMP4: bone morphogenic protein 4; PPARδ: peroxisome proliferator-activated
    receptor δ; eNOS: endothelial nitric oxide synthase; NOX: NADPH oxidase; Sirt1:
    sirtuin 1; LOX-1: lectin-like low-density lipoprotein receptor-1; JNK: c-jun N-terminal
    kinase; NF-κB: nuclear factor kappa B; PI3K: phosphatidylinositol 3-kinbase; MAPKs:
    mitogen-activated protein kinases; LPS: lipopolysaccharides; CPT-1: carnitine
    palmitoyltransferase I; FAS: fatty acid synthetase; ACCα: acetyl CoA carboxylase
    α; SREBP-1c: sterol regulatory element-binding protein 1c; MKK: mitogen-activated
    protein kinase kinase; ABCA1: ATP-binding cassette transporter A1; LXRα: liver
    X receptor α; PDGF: platelet-derived growth factor; ERK1/2: extracellular signal-regulated
    kinase 1/2; mTOR: mammalian target of rapamycin; LC3II: microtubule-associated
    protein 1 light chain 3 II; LDLR: low-density lipoprotein receptor; CYP7A1: cholesterol
    7 alpha-hydroxylase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tnf
  - Cd36
  - Bmp4
  - Myd88
  - Mir21
  - Mir126b
  - Map2k3
  - Map2k6
  - Akt1
  - Prkaa2
  - Ppara
  - Mtor
  - Nfkb1
  - Mir30a
  - Becn1
  - Nos3
  - Nr1h3
  - Jun
  - Bax
  - Ccne1
  - Hmgcr
  - Fos
  - Fas
  - Lox
  - TNF
  - CD36
  - BMP4
  - MYD88
  - MIR21
  - PPARA
  - MTOR
  - MIR30A
  - NOS3
  - NR1H3
  - JUN
  - BAX
  - HMGCR
  - FOS
  - FAS
  - LOX
  - ALOX15
  - Scarb1
  - ras
  - Hras
  - Kras
  - Rem1
  - Mir21a
  - Mir126a
  - Zhx2
  - Nkx3-1
  - Casp9
  - Cpt1a
  - Cpt1b
  - Fasn
  - Casp3
  - Ie
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - KRAS
  - HRAS
  - NRAS
  - MIR126
  - MAP2K3
  - MAP2K6
  - PRKAA1
  - PRKAA2
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - NFKB1
  - BECN1
  - ENO4
  - PPARD
  - PPARG
  - CPT1A
  - CPT2
  - CHPT1
  - ACACA
  - GPR3
  - FASN
  - FOSB
  - FOSL1
  - FOSL2
  - Paeonol
  - Paconol
  - Rasonol
  - Cholesterol
  - death
  - aroptosis  damage Lipid catabolism
---
